34
Participants
Start Date
June 30, 2008
Primary Completion Date
September 30, 2009
Study Completion Date
January 31, 2011
Atacicept
Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
Placebo matched to atacicept
Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
Research Site, Birmingham
Research Site, Aurora
Research Site, Fairfield
Research Site, Jacksonville
Research Site, East Lansing
Research Site, Philadelphia
Research Site, Houston
Research Site, Burlington
Research Site, Parkville
Research Site, Brussels
Research Site, Vancouver
Research Site, Ottawa
Research Site, Montreal
Research Site, Hradec Králové
Research Site, Olomouc
Research Site, Paris
Research Site, Freiburg im Breisgau
Research Site, Munich
Research Site, Tübingen
Research Site, Würzburg
Research Site, Beirut
Research Site, Dbaïyé
Research Site, Barcelona
Research Site, Seville
Research Site, Valencia
Research Site, Lausanne
Research Site, London
Research Site, Sheffield
Lead Sponsor
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono
INDUSTRY